Since October 20, 2011, Mr. Tony Petrello has been the CEO of Nabors Industries Limited. The CEO graduated from Harvard Law School with a Juris Doctor (JD) degree. He began working in the company in 1992, serving as the entity’s President. Nabors Industries Limited is a holding company of the Canadian Nabors Exchange Co.
Founded in 1968, Nabors Industries was initially known as Anglo Energy Limited and is headquartered in Hamilton, Bermuda. The company conducts its geothermal energy, natural gas, and oil drilling activities in many parts of the world including Africa, America, Far East, and the Middle East. Additionally, the company provides onshore well-servicing services alongside supplying offshore oil makeover rings and learn more about Tony.
Before joining the company, Mr. Tony Petrello worked in a New York based law firm known as Baker & McKenzie from 1986 to 1991. He has also been the board Deputy Chair of Nabors Industries Limited from 2003. The business guru was subsequently promoted to be the board Chairman in June 2012. Alongside this position, Mr. Petrello also serves as the Director of Stewart & Stevenson LLC (as from 28th February 2011) and Texas Children’s Hospital and resume him.
Mr. Petrello is a family man and participates in various philanthropies. The CEO is married to Cynthia Carrafa, a producer, and actress whom he began dating way back in his college years and they have an eight-year-old daughter, Carena. While still young, Carena developed Periventricular leukomalacia (PVL), a condition in which the brain white matter decays as a result of limited blood flow or oxygen.
This condition has made the couple seek several solutions that may assist their daughter to do regular activities such as talking and walking. The search led them to Texas Children’s Hospital, where they have committed themselves to fundraising activities with a lead donation of $5 million dollars. This funding is meant to facilitate research by the hospital’s Jan and Dan Duncan Neurological Research Institute.
More Visit: http://yaledailynews.com/blog/2006/02/21/alum-endows-prize-in-memory-of-lang/
Dr. Scott M. Rocklage is not new to healthcare management. The managing partner of 5 AM Ventures has been in the industry from the 70s, holding executive positions in several healthcare organizations. One of his greatest achievements in the industry was achieving the approval of Omniscan™, Cubicin®, and Teslascan® drugs by FDA. This achievement earned him lots of respect across the board, especially given the challenges that come with such approval.
Before joining 5 AM Ventures in 2003, Dr. Scott Rocklage had worked as CEO at Cubist Pharmaceuticals and Nycomed Salutar. He also had the chance to sit on the boards of management for Novira and Relypsa where he at some point served as chairman. Firms, such as Semprus, Miikana, and Ilypsa, also had hired Scott as their executive director in different times. Currently, he has a board membership for Rennovia Pulmatrix and Kinestral among others.
Dr. Scott is a highly qualified scientist, especially in the field of chemistry. His peer-reviewed publications are more than 30 while the patents associated with him are more than 100. He was privileged to attend his Ph.D. class at Massachusetts Institute of Technology (MIT) where his research supervisor was Prof. Richard R. Schrock. Prof. Richard is known for his immense contribution to the field of chemistry that led to his Nobel Prize win. Prior to the Ph.D., he had completed his bachelor’s at the University of California, Berkeley.
Scott is also respected by many for his philanthropic nature. He recently funded the renovation of laboratories at his alma mater, MIT department of chemistry.
Ideamensch featured Dr. Scott recently in an interview. He revealed that 5 AM Ventures derived its name from the word early, given that the organization is an early stage venture capital firm. He also revealed that much of his time is dedicated to the study of life science, although he spares a few hours to attend board meetings. At the office, he mostly rubs shoulders with scientists who seek his guidance on how to develop their research. Business executives also visit his office in search of medical knowledge that would help them grow their entrepreneurship within the pharmaceutical industry.